`Atty. Docket No.: GWLG-017US-CIP
`Response to Final Office Action
`
`
`
`(Currently Amended) The method of claim 13, admaflybeenrprwfiig—deteetmg—the
`
`presenee—and wherein the level of circulating BDNF is determined in the sample—byL
`
`
`
`(Currently Amended) The method of claim 15, admaflybeernprwfiig—deteetmg—the
`
`presenee—and wherein the level of ZAG is determined in the sample—byheentaeti-ng—the
`
`
`
`(Previously presented) A method of determining levels of circulating BDNF and CA-125
`
`15.
`
`l6.
`
`17.
`
`in a mammal comprising:
`
`detecting the presence of BDNF and CA-125 in a plasma sample from the mammal
`
`by contacting the sample with an anti-BDNF antibody and an anti-CA-125 antibody;
`
`detecting binding between the anti-BDNF antibody and BDNF and between the
`
`anti-CA-125 antibody and CA-125 in the sample; and
`
`determining the circulating levels of BDNF and CA-125 in the mammal based on
`
`the amount of antibody binding.
`
`